Výsledky vyhledávání - "Marie-Ange Lentz"

A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971

Autor: Philippe Chollet, Jaak Van Der Auwera, Bruno Coudert, Sylvie Giacchetti, Georges Fillet, Domenico Amoroso, Christian Focan, Marie Ange Lentz, Benoit Baron, Dominique Genet, Alberto Zambelli, Francis Lévi, Sandrine Marreaud, Fabienne Biville, Frédérique Cvickovic, Thierry Gorlia

Publikováno v: Chronobiology international. 25(5)

Studies in animals synchronized with an alternation of 12 h of light and 12 h of darkness have showed that hematological and systemic toxicities could be reduced if vinorelbine were administered 19 or 23 hours after light onset (HALO), corresponding

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8d4f6faa101ac6e6d5537ffd88e0a76
https://pubmed.ncbi.nlm.nih.gov/18780198

Zobrazit plný text záznamu

Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC)

Autor: Theo Ruers, Cornelis J. A. Punt, Frits van Coevorden, Jean-Pierre Pierie, Inne Borel Rinkes, Jonathan A. Ledermann, Graeme John Poston, Wolf O. Bechstein, Marie-Ange Lentz, Murielle E. Mauer, Eric Van Cutsem, Manfred P. Lutz, Bernard Nordlinger

Publikováno v: Journal of Clinical Oncology. 33:3501-3501

3501 Background: This study evaluates the benefit of combining systemic chemotherapy (CT) with local tumor destruction by RFA in patients with unresectable CRC LM up to 9 lesions and without extrahepatic disease. Overall survival (OS) at 30 months an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d48c2210c1d0dbb70a8b42c03a66f92c
https://doi.org/10.1200/jco.2015.33.15_suppl.3501

Zobrazit plný text záznamu

Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group

Purpose In two previous randomized trials, the adjustment of chemotherapy delivery to circadian rhythms improved tolerability and anticancer activity compared with constant-rate infusion during 5 days in patients with metastatic colorectal cancer. Pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98b48a7732cac90c7939c1fd69c3659b
http://hdl.handle.net/2318/101575

Zobrazit plný text záznamu

Tamoxifen as a single agent for advanced melanoma in postmenopausal women. A phase II study of the EORTC Malignant Melanoma Cooperative Group

Autor: Rona M. MacKie, J.F. Bierhorst, Ph. Rümke, André S Th A. Planting, Marie Ange Lentz, Eva B. Bröcker, Ferdinand Lejeune, Ulrich R. Kleeberg

Publikováno v: Melanoma research. 2(3)

Between 1983 and 1989 a phase II study was carried out by the EORTC Malignant Melanoma Cooperative Group in which postmenopausal women with advanced melanoma but a good performance status received tamoxifen, 40 mg per day, as a single agent. From 12

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc2744cc775a176ef07239b1f581bbdb
https://pubmed.ncbi.nlm.nih.gov/1450668

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání